Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Latest Articles
Submit an article Journal homepage
34
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects

Cheng Suna Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China;b School of Pharmacy, Anhui Medical University, Hefei, ChinaView further author information
,
Hao Liua Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China;b School of Pharmacy, Anhui Medical University, Hefei, ChinaView further author information
,
Ziwei Ouyanga Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China;b School of Pharmacy, Anhui Medical University, Hefei, ChinaView further author information
,
Jie Dinga Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, ChinaView further author information
,
Qin Zhanga Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, ChinaView further author information
,
Hongjie Mac Shenzhen Kexing Pharmaceutical Co., Ltd, Shenzhen, ChinaView further author information
,
Dandan Xuc Shenzhen Kexing Pharmaceutical Co., Ltd, Shenzhen, ChinaView further author information
,
Qian Zhanga Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, ChinaView further author information
,
Renpeng Zhoua Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, ChinaCorrespondence[email protected]
View further author information
,
Mingming Yangc Shenzhen Kexing Pharmaceutical Co., Ltd, Shenzhen, ChinaCorrespondence[email protected]
View further author information
&
Wei Hua Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4809-7601View further author information
ORCID Icon show all
Received 05 Nov 2023, Accepted 17 Apr 2024, Published online: 30 Apr 2024

References

  • Rehman SU, Shafique L, Ihsan A, et al. Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. Pathogens. 2020 Mar 23;9(3):240. doi: 10.3390/pathogens9030240
  • Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021 Dec 24;374(6575):1586–1593. doi: 10.1126/science.abl4784
  • Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - final report. N Engl J Med. 2020 Nov 5;383(19):1813–1826. doi: 10.1056/NEJMoa2007764
  • Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022 Feb 10;386(6):509–520. doi: 10.1056/NEJMoa2116044
  • Zhang Y, Sun Y, Xie Y, et al. A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir. Signal Transduct Target Ther. 2023 Sep 22;8(1):360. doi: 10.1038/s41392-023-01587-1
  • Yang J, Petitjean SJL, Koehler M, et al. Author correction: molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2021 May 14;12(1):2996. doi: 10.1038/s41467-021-23498-x
  • Yadav R, Chaudhary JK, Jain N, et al. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells. 2021 Apr 6;10(4):821. doi: 10.3390/cells10040821
  • Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020 Oct;92(10):2249. doi: 10.1002/jmv.26234
  • Nesterenko PA, McLaughlin J, Tsai BL, et al. HLA-A(*)02: 01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Rep. 2021 Dec 28;37(13):110167. doi: 10.1016/j.celrep.2021.110167
  • Faheem KB, Sekhar K, Sekhar KVGC, et al. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Bioorganic Chemistry. 2020 Nov;104:104269. doi: 10.1016/j.bioorg.2020.104269
  • Blair HA. Correction to: Remdesivir: a review in COVID-19. Drugs. 2023 Sep;83(14):1349. doi: 10.1007/s40265-023-01937-x
  • Wang Z, Yang L, Song XQ. Oral GS-441524 derivatives: next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol. 2022;13:1015355. doi: 10.3389/fimmu.2022.1015355
  • Li Y, Yang B, Quan Y, et al. Advancement of prodrug approaches for nucleotide antiviral agents. Curr Top Med Chem. 2021;21(32):2909–2927. doi: 10.2174/1568026621666210728094019
  • Zhou Q, Yang S, Cao L, et al. Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1’-CN-4-aza-7,9-dideazaadenosine C-nucleoside. Signal Transduct Target Ther. 2023 Jan 12;8(1):27. doi: 10.1038/s41392-023-01310-0
  • Pagliano P, Sellitto C, Ascione T, et al. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opin Drug Discov. 2022 Dec;17:(12):1299–1311.
  • Pharmaceuticals and Medical Devices Agency. Tokyo: Pharmaceuticals and Medical Devices Agency; c2022. Gilead Sciences. Section 2.7-clinical summary of remdesivir common technical document. 2020. Available from: https://www.pmda.go.jp/drugs/2020/P20200518003/230867000_30200AMX00455_K100_1.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.